Research Analysts Issue Forecasts for PepGen FY2029 Earnings

PepGen Inc. (NASDAQ:PEPG) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for PepGen in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share.

PepGen (NASDAQ:PEPG) last issued its earnings results on Thursday, November 7th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21.

Several other equities research analysts have also recently commented on the company. Bank of America cut PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a report on Monday, December 16th. Wedbush dropped their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.

PepGen Price Performance

NASDAQ PEPG opened at $1.29 on Friday. The company has a market cap of $42.05 million, a PE ratio of -0.43 and a beta of 1.66. The stock’s 50 day simple moving average is $3.76 and its 200-day simple moving average is $7.40. PepGen has a 1-year low of $1.28 and a 1-year high of $19.30.

Hedge Funds Weigh In On PepGen

Several institutional investors and hedge funds have recently added to or reduced their stakes in PEPG. Point72 DIFC Ltd purchased a new stake in shares of PepGen during the 2nd quarter worth approximately $42,000. American Century Companies Inc. raised its position in shares of PepGen by 19.9% in the 2nd quarter. American Century Companies Inc. now owns 20,028 shares of the company’s stock worth $320,000 after buying an additional 3,326 shares during the period. Jane Street Group LLC raised its position in shares of PepGen by 29.1% in the 3rd quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock worth $237,000 after buying an additional 6,254 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of PepGen in the 4th quarter worth $26,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of PepGen in the 3rd quarter worth $95,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.